Latest Breaking News On - Nephrology kidney week - Page 1 : comparemela.com

Pegcetacoplan Offers Potential Benefit in Post-Transplant C3G, IC-MPGN

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.

United statesFadi fakhouriCaroline baumalEuropean renal association congressUniversity of lausanne fadi fakhouriApellis pharmaceuticals incLausanne university hospitalAmerican society of nephrology kidney weekLausanne universityAmerican societyNephrology kidney weekEuropean renal associationApellis pharmaceuticals

How Vertex became the VIP of Alpine s exclusive data room

How Vertex became the VIP of Alpine s exclusive data room
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesAmerican society of nephrology kidney weekVertex pharmaceuticalsWorld congressAlpine immune sciencesAfter alpine immune sciencesAmerican societyNephrology kidney weekSan franciscoVertex executive chairman jeffrey leiden

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection

United statesStephen jasperEliezer katzDavid alexandrec grosAllan kirkJames robinsonDiabetes research foundationCure allianceEledon pharmaceuticalsGilmartin groupEledon pharmaceuticals incExchange commissionAmerican society of nephrology kidney weekUniversity of chicago transplantation instituteBerry company public relationsChief executive officer

FDA Grants Orphan Drug Designation to Felzartamab for Kidney Transplant Recipients

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

United statesUptal patelDrug administration for primary membranous nephropathyAmerican society of nephrology kidney weekOrphan drug designationHuman immunology biosciencesAmerican societyNephrology kidney weekBreakthrough therapy designationBio receivesDrug designationAntibody mediated rejectionKidney transplantBio announces positive phasePrimary membranousDrug administration

Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

22.02.2024 - Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch off to a strong start, .

United statesFosun pharmaArnold silvaMike raabCaitlin lowieDavid spiegelPhilip schoenfeldAmerican society of nephrology kidney weekInvestment corpExchange commission onCompany annual report on formJohnd dingell va medical centerArdelyx incExchange commissionJapanese ministry of healthBoise kidney hypertension institute